



**Anand S. Srivastava, M.S., Ph.D.**

Presidente y Co-fundador  
anand@giostar.com

El Dr. Anand Srivastava ha estado asociado con distintas instituciones y universidades de EE.UU. En conjunto con University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), ha desarrollado diversos programas de investigación. Tiene amplia experiencia trabajando con células madres, y su investigación se ha documentado a través de publicaciones en revistas científicas.

El Dr. Srivastava es Presidente y Co-fundador del **Global Institute of Stem Cell Therapy and Research (GIOSTAR)**, con sede en San Diego, California, EE.UU. La compañía fue consolidada bajo la visión de proveer terapia basada en células madre en ayuda de quienes sufren de enfermedades degenerativas o genéticas alrededor del mundo; algunos ejemplos de enfermedades son Parkinson, Alzheimer, Autismo, Diabetes, Condiciones cardíacas, Lesión de la columna vertebral, entre otras. GIOSTAR se perfila como líder en el desarrollo de la tecnología más avanzada basada en células madre, sustentada por científicos con publicaciones pioneras en el área de la biología de las células madre. El principal objetivo de la empresa es descubrir y desarrollar enfermedades humanas con base en la terapia de células madre y sus productos. La **Medicina Regenerativa** ofrece una promesa para el tratamiento de enfermedades que se habían catalogado previamente como incurables.

El Dr. Srivastava trabaja actualmente como director del Programa de Células Madre; y en el desarrollo de políticas y programas basados en células madre para los siguientes gobiernos y organizaciones:

1. Colaboró en la estación central de células madre en Salk Research Institute, San Diego, USA
2. Trabajó en el Programa de células madre de University of California, Los Angeles, USA
3. Trabajó para el Japanese Research Institute en el desarrollo del Programa genómico en Japón.
4. Director del Programa de células madre de GIOSTAR en el estado de Gujarat, India
5. Director del Programa de células madre de GIOSTAR en el estado de Madhya Pradesh, India
6. Director del Programa de células madre de GIOSTAR en el estado de Chattishgarh, India
7. Director del Programa de células madre de GIOSTAR en University of Baroda, Gujarat, India
8. Asesor en el Programa de células madre en Asian Medical School, Kyrgyzstan.

## **CARGOS OCUPADOS PRO EL Dr. SRIVASTAVA (1997-a la fecha):**

1. **Chairman & Cofounder (2008-till date):** Global Institute of Stem Cell Therapy and Research, San Diego, CA. USA.
2. **Visiting Scientist (2009-2012):** Department of Stem Cell Biology, Burnham Research Institute for Medical Science, San Diego, CA, USA.
3. **Visiting Associate Researcher (2009-2010):** Department of Molecular, Cell and Development Biology, University of California Los Angeles (UCLA), CA, USA.
4. **Researcher (2008–2009):** Stem Cell Core Facility, The Salk Institute for Biological Studies, La Jolla, CA, USA.
5. **Associate Project Scientist (2006-2008):** Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA.
6. **Assistant Project Scientist (2000-2006):** Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
7. **Visiting Fellow (1997-2000):** National Research Institute, Nansei, Mie, JAPAN

## **EDICIONES ESPECIALES SOBRE CÉLULAS MADRE EN REVISTAS DEDICADAS AL DR. SRIVASTAVA**

1. **Current Topics of Medicinal Chemistry** among top five medicinal chemistry journal devoted its special issue of stem cell to Dr. Srivastava in 2010.
2. **Stem Cell International** devoted its special issue on stem cells to Dr. Srivastava in 2012.
3. **Potentials of ES cell therapy in neurodegenerative diseases** (Curr Pharm Des; 2008;14:3873-9) by Dr. Srivastava is still holding number one position among top 20 articles published since 2008 in the field rated by BIOmedLib in 2012 and 2015.

## **BECAS/PREMIOS:**

- 2014**      Awarded with “**USA Congressional Award**” for his contribution in the field of Stem Cell Science. USA.
- 2013**      Awarded with “**Asian Heritage Award**” for his contribution in the field of Stem Cell Science. USA.
- 2003**      Awarded with “**NIMA (National Integrated Medical Association) Outstanding Scientist**” award from NIMA, India.
- 2003**      Awarded with “**Excellent Scientist Award**” from Bharat Vikas Parisad, India for continuous excellent performance in the life science research. The 18<sup>th</sup> International Congress of Clinical Chemistry and Laboratory Medicine Kyoto “**Excellent Poster Award**”, Kyoto, Japan.
- 2002**      “**Best Scientist Award**” for excellent contribution in the field of life science research from Kayastha Maha Sabha, Varanasi, India.
- 1998-2000:** “**Long-term STA/JISTEC Award**” (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship award for two year from government of Japan.
- 1997-1998:** “**Short-term STA/JISTEC Award**” (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship Award for three months from government of Japan (October 1997- January 1998).
- 1997-1998:** Awarded with “**Research Associate-ship award**” from CSIR (Council of Scientific and Industrial Research) Government of India.
- 1990-1995:** “**CAS (Center of Advanced Study) Award**” in Zoology. A doctoral research

fellowship award from Government of India.

### **SUBVENCIONES Y PREMIOS RELACIONADOS CON EL Dr. ANAND SRIVASTAVA**

1. Government of India grant to establish Red Blood Cell from Stem cell (2015 to 2017)
2. Canada Grand Challenge grant award, Canada, Development of tuberculosis (TB) test in TB patients, (2013-2014).
3. Government of India grant to establish stem cell transplant center (2009 – till date).
4. Broad Medical Research Program, Repair of Crohn's Disease with Stem Cells, (2004-2005)
5. National Institute of Health, USA (NIH/NIDDK R01 grant), Mixed Chimerism Following Prenatal Tolerance Induction, (1999-2005).
6. Ronald McDonald House Charities Medical Grant, Lentiviral Gene Transfer in  $\beta$ -Thalassemic Mice, (2000-2005).
7. National Institute of Health, USA (NIH-K08 grant), *In utero* transplantation of stem cell in  $\beta$ -thalassemic mice, (2000-2002)
8. Japan Science and Technology award (JISTEC Grant), Government of Japan, Cloning and gene expression during development (1988-2000).
9. Japan Science and Technology award (JISTEC Grant), Government of Japan, Expression of enzymes and protein during energy metabolism (1997-1998).
10. Center of Scientific and Industrial Research (CISR) grant, Government of India under young scientist award (1996-1997).

### **A CONTINUACIÓN SE RESUMEN LOS PRINCIPALES LOGROS CIENTÍFICOS DEL DR. SRIVASTAVA.**

1. Dr. Srivastava developed the animal material free and serum free Human embryonic Stem cell culture condition to use the Human ES cells to treat the human diseases.
2. Dr. Srivastava for the first time showed that if the ES cell injected into developing fetuses in utero takes participation in development of all body of a living organism.
3. For the first time he showed that ES cell is better accepted by the transplanted animals in comparison to adult stem cells.
4. For the first time he showed the way to generate the high number of pre-erythrocytes using glucocorticoid hormone. Which may be use to treat several blood diseases.
5. For the first time Using ES cells he generated the high number of CD34+ expressing a kind of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune reconstitution and blood diseases.
6. For the first time he showed the molecular mechanism behind the regulation of ES cell differentiation into hematopoietic cells.
7. For the first time he showed that ES cells automatically recognize the damage portion of the brain and can be used to repair the damage brain.
8. For the first time he showed that ES cell can be used to treat the Crohn's disease a kind of colon cancer.
9. For the first time, he demonstrated that the mammalian fetuses can be programmed inside the mother uterus to face the challenges of the future possible infection. This finding is very important to develop the advanced therapy for any fatal disease such as cancer and AIDS. Utilizing these techniques, fetuses can be given information about all possible infections and the capability to counter those infections and disease.
10. He has demonstrated for the first time that it is easy to correct the genetic diseases in developing fetus *in utero* in comparison to adult animals.

11. He has shown for the first time that the lung cancer cells can be treated with the help of plant product curcumin and can be used as effective cancer therapeutic agent. He also demonstrated that how curcumin regulated the genes related to programmed death of cancerous cell. Finding help in development of non-toxic, less expensive, easily available drug for cancer.
12. The biggest problem in the treatment of cancer and other diseases is the non-specific distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava for the first time developed a technique that can help in targeting the diseased tissues using the tissue receptor binding peptide ligands. These techniques can be used for targeted delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the mother uterus without harming the normal tissues of mother and fetus.
13. For the first time, He demonstrated the insertion of foreign pancreas enzyme specific gene promoter into the developing animals embryo and successfully shown the incorporation and regulation of pancreatic enzyme in the control of inserted gene. This is very important finding and proves that the defective genes can be replaced easily and effectively by the normal functional genes during the development of animals. This finding will help in the change of defective genes of insulin hormone, which is present in the pancreas of diabetic patients and many other genetic diseases also.
14. For the first time, He reported the gene sequence of all important pancreatic enzymes (three isoform of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three forms of carboxypeptidases and lipase) and its evolutionary relationship with human. Also, he reported first time the regulation of digestion by these enzymes in the alimentary canal during digestion of proteins in the developing animals.
15. For the first time, He cloned and sequenced two types of human homologue of Vitamin D receptor gene from Japanese flounder, which is most important receptor, which help in the development of bone. Before my report, characters of this gene were not known in Japanese flounder. This finding helped in the understanding of the genetic evolution of mammals.
16. For the first time, he cloned and sequenced the homologue of human placental protein, PP11, and mouse T cell specific, Tcl-30, in pancreas of Japanese flounder, this study suggest that these genes evolved from the fish pancreas and in fish it helps in synthesizing the digestive enzymes but during the evolution its function got changed and work differently in the mammalian placenta. This was very important finding related to this rare gene.
17. For the first time, He has shown that the Hox and sonic hedgehog genes regulate the development of bones and respiratory organs. He also demonstrated that how these genes could be regulated artificially. This was very important finding because it gives the idea that how genes regulate the development of organs.
18. For the first time, He has purified and characterized the human homolog of AAT and ASPT enzymes, which is the basic clinical marker in all the infection and major marker of liver function test.
19. For the first time, he demonstrated the co-ordination of AAT and ASPT enzymes in the production of energy through the amino acids after aerobic respiration.
20. For the first time, he has shown that according to metabolic demand of the body AAT and ASPT genes synthesized additional forms of its isoform to cope up with the extra energy demand and work as an “on” and off” switch.

## **PUBLICACIONES CIENTÍFICAS (más de 50 publicaciones).**

1. Prabhat Soni and **Anand Srivastava**; Mesenchymal stem cells may be a credible alternative therapy to fight with COVID-19 pandemic. *J Stem Cell Res Ther.*; 6(2): 79–80: 2020.
2. Esquivel Diana, Garza Daniel and **Srivastava Anand**; Mesenchymal Stem Cell Therapy: An Alternative Approach to Treat Chronic Obstructive Pulmonary Disease. *Stem Cell Res Ther.*; 4(1): 1035: 2020.
3. Renganathan S, **Srivastava A**, Pillai RG.; Dhanwantaram kashayam, an Ayurvedic polyherbal formulation, reduces oxidative radicals **and** reverts lipids profile towards normal in diabetic rats. *Biochem Biophys Rep.* 25; 22:100755: 2020.
4. Seetharaman, Rajasekar; Mahmood, Anjum; Kshatriya, Prashant; Patel, Divyang; **Srivastava, Anand**, An Overview on Stem Cells in Tissue Regeneration: *CPD*: 1-13,2019.
5. Stem Cell Transplant for Advanced Stage Liver Disorders: Current Scenario and Future Prospects. Mahmood A, Seetharaman R, Kshatriya P, Patel D, Srivastava AS. *Curr Med Chem.* 1-16: Oct 4: 2019 doi: 10.2174/0929867326666191004161802.
6. Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris: A Case Study. Seetharaman R, Mahmood A, Kshatriya P, Patel D, **Srivastava A**. *Case Reports in Dermatological Medicine.* May 2019; Article ID 8309103. <https://doi.org/10.1155/2019/8309103>.
7. **Diabetes: stem cells offering healthy promises.** Saraswat A, **Srivastava A**. *J Stem Cell Res Ther.* 2018 May, 4(3):46-47. DOI: [10.15406/jsrt.2018.04.00113](https://doi.org/10.15406/jsrt.2018.04.00113).
8. **Role of cell based approaches in cancer immunotherapy.** Mahmood A, **Srivastava A**, Srivastava S, Pandya H, Neel Khokhani, Divyang Patel, Rangnath Mishra. *J Stem Cell Res Ther.* May 2017, 2(5): 00077. DOI: [10.15406/jsrt.2017.02.00077](https://doi.org/10.15406/jsrt.2017.02.00077).
9. **Inflammatory Bowel Diseases: Current Therapeutic Approaches and Potential of using Stem Cells.** Mishra T, Sarswat A, Mishra K, **Srivastava AS**. *J Stem Cell Res Ther.* 2017 Feb. 2(2): 00057. DOI:[10.15406/jsrt.2017.02.00057](https://doi.org/10.15406/jsrt.2017.02.00057).
10. Cardiovascular diseases: Recent developments in regenerative medicine. Mahmood, A., Pandya, H., Rajasekar,S., Patel, D., **Srivastava A.** **Journal of Stem Cell Research & Therapeutics.** 2017, July 3(2):00095. doi: 10.15406/jsrt.2017.03.00095.
11. Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice. Sharma V, Nayak J, DeRossi C, Charbono A, Ichikawa M, Ng BG, Grajales-Esquivel E, **Srivastava A**, Wang L, He P, Scott DA, Russell J, Contreras E, Guess CM, Krajewski S, Del Rio-Tsonis K, Freeze HH. *FASEB J.* 2014 Apr 28(4):1854-69. doi: 10.1096/fj.13-245514.
12. Basal expression of pluripotency-associated genes can contribute to stemness property and differentiation potential. Dadheech N, Srivastava A, Belani M, Gupta S, Pal R, Bhonde RR, **Srivastava AS**, Gupta S. *Stem Cells Dev.* 2013 Jun 15;22(12):1802-17. doi: 10.1089/scd.2012.0261.

13. Therapeutic potential of mesenchymal stem cells in regenerative medicine. Patel DM, Shah J, **Srivastava AS.**, Stem Cells Int. 2013 Feb 496218. doi: 10.1155 / 2013 / 496218.
14. Patel DM, Shah J, **Srivastava AS.**, Therapeutic potential of mesenchymal stem cells in regenerative medicine, Stem Cells Int. 2013;2013:496218
15. Srivastava AS, Stem cells., Curr Top Med Chem.;11:1591, 2011.
16. Dhawan P, Ahmad R, Srivastava AS, Singh AB., Cancer stem cells and colorectal cancer: an overview. Curr Top Med Chem. 11:1592-8, 2011.
17. Sudip Mandal, Anne Lindgren, **Anand Srivastava** and Utpal Banerjee. Role of mitochondria in self-renewal, early differentiation and tumorigenicity of pluripotent stem cell. **Stem Cells, 29:486-95, 2011.**
18. Basak GW, Yasukawa S, Alfaro A, Halligan S, **Srivastava AS**, Minev B, Carrier E. Human embryonic stem cells hemangioblast express HLA-antigens. **J Transl. Med., 7:27-36; 2009.**
19. Grzegorz Wladyslaw Basak, **Srivastava AS**, Rakesh Malhotra, Ewa Carrier Multiple Myeloma Bone Marrow Niche. **Curren. Pharm. Biotech, 10:345-6, 2009.**
20. **Srivastava AS**, Malhotra R, Jason Sharp and Berggren T. Potentials of ES Cell therapy in Neurodegenerative Diseases. **Curren. Pharm. Design, 14:3873-9; 2008.**
21. **Anand S. Srivastava**, Rangnath Mishra, Sharmeela Kausal, Dharam P. Chauhan and Ewa Carrier; Clinical Prospects of Embryonic Stem Cells in treatment of Hematopoietic Disorders. **Curren. Pharm. Biotech. 8: 51-56, 2007.**
22. **Anand S. Srivastava**, Elena Nedelcu, Babak Esmaeli-Azad, Rangnath Mishra and Ewa Carrier; Thrombopoietin Enhances Generation of CD 34+ Cells from Human Embryonic Stem Cells. **Stem Cells, 25:1456-61, 2007.**
23. **Anand S. Srivastava**, Dharam Chauhan, Zong Ling Feng, Hyun S Kim and Ewa Carrier; Transplantation of embryonic stem cell in *CDIL10*<sup>-/-</sup> *KO* mouse, an animal model of colitis, antagonizes the manifestation of Crohn's Disease. **BBRC 361:953-959, 2007.**
24. **Anand S. Srivastava**, Steve Shenouda, Rangnath Mishra and Ewa Carrier; Transplanted Embryonic Stem cells Successfully Survive and Proliferate in Brain and Migrate to Damaged Regions of the Brain. **StemCells, 24:1689-94, 2006.**
25. **Anand S. Srivastava**, Sharmeela Kaushal, Rangnath Mishra, Thomas A. Lane and Ewa Carrier; Dexamethasone facilitates erythropoiesis in murine embryonic stem cell differentiating into hematopoietic cells in vitro. **BBRC, 346:508-16, 2006.**
26. Marta R., Mara G., **Srivastava A.S.**, Matthew, C. W., Kilian S., Carrier E., and Zanetti M.; Immunity over tolerance targeting fetal liver B cells. **Vaccine, 23:4273-82, 2005.**

27. Feng Z, **Srivastava AS**, Mishra R, Carrier E., A regulatory role of Wnt signaling pathway in the hematopoietic differentiation of murine embryonic stem cells. **Biochem. Biophys. Res. Commun.**, **324:1333-9, 2004.**
28. **Srivastava A.S.**, Chauhan, D.P. and Carrier E.; *In utero* detection of T7 phage in the fetal tissues after systemic administration to pregnant mice. **Biotechniques**, **37:81-83, 2004.**
29. **Srivastava A.S.**, Kaido T., Carrier E.; Immunological factors that affect the *in vivo* fate of T7 phage in the mouse. **J of Virol. Meth.**, **115:99-104, 2004.**
30. **Srivastava A.S**, G. Radhakrishna Pillai, Dharam P. Chauhan and Ewa Carrier; Induction of apoptosis in human lung cancer cells by dietary Curcumin. **Cancer letters**, **208:163-170, 2004.**
31. M. E. Moustafa, **A. S. Srivastava**, E. Nedelcu, S. Shenouda and E. Carrier; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. **Transplantation**, **78:1274-1282, 2004.**
32. **A. S. Srivastava**, M. E. Moustafa, S. Shenouda, D. P. Chauhan and E. Carrier; In utero gene therapy: prospect and future. **Curren. Pharm. Des.**, **10:3663-72, 2004.**
33. **Anand S. Srivastava**, Ichiro Oohara, Tohru Suzuki, Steve Shenouda, Surender N. Singh, Dharam P. Chauhan and Ewa Carrier; Purification and properties of cytosolic alanine aminotransferase from the liver of two fresh-water fish species, *Clarias batrachus* and *Labeo rohita*. **Comp. Biochem. Physiol-B**, **137:197-207, 2004.**
34. Suzuki,T., **Srivastava,A.S.** and Kurokawa,T., Paralichthys olivaceus COL1A1 mRNA for type 1 collagen alpha 1, complete cds. **Nat. Cent. Biotech. Infor., USA, AB196513, 2004.**
35. Suzuki,T., **Srivastava,A.S.** and Kurokawa,T., Paralichthys olivaceus COL1A2 mRNA for type 1 collagen alpha 2, complete cds. **Nat. Cent. Biotech. Infor., USA, AB196514, 2004.**
36. Suzuki,T., **Srivastava,A.S.** and Kurokawa,T., Paralichthys olivaceus COL1A3 mRNA for type 1 collagen alpha 3, partial cds. **Nat. Cent. Biotech. Infor., USA, AB196515, 2004.**
37. Suzuki,T., **Srivastava, A.S.** and Kurokawa,T., Paralichthys olivaceus COL1A1 gene for type 1 collagen alpha 1, promoter region. **Nat. Cent. Biotech. Infor., USA, AB196516, 2004.**
38. Suzuki,T., **Srivastava,A.S.** and Kurokawa,T., Paralichthys olivaceus COL1A3 gene for type 1 collagen alpha 3, promoter region. **Nat. Cent. Biotech. Infor., USA, AB196517, 2004.**
39. **Srivastava A.S.**, Kurokawa T., Suzuki T.; Molecular cloning and cDNA sequence analysis of carboxypeptidases A1, A2 and B from the Japanese flounder *Paralichthys olivaceus*. **Comp. Biochem. Physiol-B**, **135:593-599, 2003.**
40. Hassan S., Jody D., Gilpin E.A., **Srivastava A.S.**, Carrier E.; Tolerance and immunity following *in utero* transplantation of allogeneic fetal liver cells: The cytokine shift. **Cell Transplantation**, **12:75-82, 2003.**

41. Tohru Suzuki, **Anand S. Srivastava**, Tadahide Kurokawa; A homologue of human placental protein, PP11, and mouse T cell-specific, Tcl-30, in exocrine pancreas of a teleost *Paralichthys olivaceus*. **Comp. Biochem. Physiol-B**, **133:325-329**, 2002.
42. **Anand S. Srivastava**, Tohru Suzuki, Tadahide Kurokawa; mRNA expression of pancreatic enzyme precursors and estimation of protein digestibility in first feeding larvae of the Japanese flounder, *Paralichthys olivaceus*. **Comp. Biochem. Physiol-A**, **132:629-635**, 2002.
43. Hassan S., Jody D., **Srivastava A.S.**, Gilpin E., Lee T, Carrier E.; Alloreactivity following *in utero* transplantation of cytokine-stimulated hematopoietic stem cells: The role of recipient CD4<sup>+</sup> cells. **Exp. Hematol.**, **30:617-624**, 2002.
44. Tohru Suzuki, **Anand S. Srivastava**, Tadahide Kurokawa; cDNA Cloning and phylogenetic analysis of pancreatic serine proteases from Japanese flounder, *Paralichthys olivaceus*. **Comp. Biochem. Physiol-B**, **131:63-70**, 2002.
45. Suzuki, T., **Srivastava, A.S.** and Kurokawa, T; *Paralichthys olivaceus* ppsb mRNA for pancreatic protein with two somatomedin B domains. **Nat. Cent. Biotech. Infor., USA**, **AB035673**, 2002.
46. Tohru Suzuki, Tadahide Kurokawa, **Anand S. Srivastava**; Induction of bent cartilaginous skeletons and undulating notochord in flounder embryos by disulfiram and  $\alpha$ ,  $\alpha'$ -Dipyridyl. **Zoological Science**, **18:345-351**, 2001.
47. Tohru Suzuki, Nobuo Suzuki, **Anand S. Srivastava**, Tadahide Kurokawa; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, *Paralichthys olivaceus*. **Biochem. Bio. Res. Commu.** **270:40-45**, 2000.
48. Suzuki,T., Suzuki,N., **Srivastava, A.S** and Kurokawa,T; *Paralichthys olivaceus* VDRb mRNA for vitamin D receptor b, complete sequence. **Nat. Cent. Biotech. Infor., USA**, **AB037673**, 2000.
49. Suzuki,T., Suzuki,N., **Srivastava, A.S** and Kurokawa,T; *Paralichthys olivaceus* VDRb mRNA for vitamin D receptor b, complete sequence. **Nat. Cent. Biotech. Infor., USA**, **AB037674**, 2000.
50. Suzuki,T. and **Srivastava, A.S**; Keratin expressed at esophagus and skin of flounder larvae. **Nat. Cent. Biotech. Infor., USA**, **AB049616**, 2000.
51. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Experimental induction of jaw and gill skeletal malformation in Japanese flounder, *Paralichthys olivaceus*, larvae. **Aquaculture**, **185: 175-187**, 2000.
52. Suzuki T., **Srivastava A.S.**, Kurokawa T.; *Hoxb-5* is expressed in gill arch 5 during pharyngeal arch Development of flounder *Paralichthys olivaceus* embryos. **Int.J.Dev.Biol**, **43:357-559**, (1999).

53. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for trypsinogen 1. **Nat. Cent. Biotech. Infor., USA, AB029750, (1999).**
54. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for trypsinogen 2. **Cent. Biotech. Infor., USA, AB029751, (1999).**
55. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for trypsinogen 3. **Cent. Biotech. Infor., USA, AB029752, (1999).**
56. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 1. **Cent. Biotech. Infor., USA, AB029753 (1999).**
57. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 2. **Cent. Biotech. Infor., USA, AB029754 (1999).**
58. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for elastase 1 precursor. **Cent. Biotech. Infor., USA, AB029755, (1999).**
59. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for elastase 2 precursor. **Cent. Biotech. Infor., USA, AB029756, (1999).**
60. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for elastase 3 precursor. **Cent. Biotech. Infor., AB029757, (1999).**
61. Suzuki T., **Srivastava A.S.**, Kurokawa T.; Japanese flounder mRNA for elastase 4 precursor. **Cent. Biotech. Infor., USA, AB029758, (1999).**
62. **Srivastava A.S.**, Oohara I., Suzuki T., Singh S.N.; Activity and expression of aspartate aminotransferase during reproductive cycle of a fresh water fish, *Clarias batrachus*. **Fish Physiol.Biochem., 20:243-250,1999.**
63. **Srivastava A.S.**, Oohara I., Suzuki T., Singh S.N.; Activity and expression of Glutamate Oxaloacetate Transaminase during reproductive cycle of a fresh water fish *Labeo rohita*. **Fisheries Science, 64(4):621-626,1998.**
64. **Srivastava A.S.**, Trigun S.K., Singh S.N.; Activity of cytosolic and mitochondrial alanin aminotransferase during pre-spawning phase in air-breathing and non air-breathing fishes. **J.Sci.Res., 47:33-38,1997.**